MorphoSys, Novartis expand therapeutic antibody collaboration through 2011

By Lisa Kerner

Charlotte, N.C., June 26 - MorphoSys AG said it has expanded its existing therapeutic antibody collaboration with Novartis through May 2011.

The two companies originally formed a strategic alliance in May 2004 to jointly develop new antibody-based therapeutics against a range of illnesses, with Novartis becoming MorphoSys' largest shareholder.

Under the extended agreement, Novartis will increase the number of new therapeutic antibody projects annually, resulting in increased levels of funding for research and development at MorphoSys.

Novartis will have the option to access the MorphoSys HuCAL GOLD library and certain HuCAL affinity optimization technology.

Annual license fees will increase, but commercial license fees, research and developmental milestones, and royalties on marketed antibody products remain unchanged.

Located in Munich, Germany, MorphoSys develops and applies technologies for the production of synthetic antibodies to accelerate drug discovery. and target characterization.

Novartis, based in Basel, Switzerland, researches, develops, manufactures, and markets health care products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.